Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.36 |
| ▸ | GPR6 | P46095 | 7/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011824 | 1.00 | MGLL (0.37) | MGLLHDAC4GPR6ABHD6HTR2A | |
| SCHEMBL27139040 | 0.87 | MGLL (0.36) | MGLLGPR6HTR2AHTR2C | |
| SCHEMBL30012117 | 0.82 | MGLL (0.41) | MGLLGPR6 | |
| SCHEMBL27147661 | 0.80 | PTGS2 (0.39) | HTR2AHTR2C | |
| SCHEMBL25324828 | 0.80 | MGLL (0.40) | MGLLGPR6HTR2AHTR2C | |
| SCHEMBL27246264 | 0.79 | MGLL (0.40) | MGLLGPR6HTR2AHTR2C | |
| SCHEMBL30012659 | 0.78 | MGLL (0.40) | MGLLHDAC4ABHD6 | |
| SCHEMBL27151949 | 0.78 | MGLL (0.40) | MGLLHDAC4ABHD6 | |
| SCHEMBL23150537 | 0.78 | HTR2A (0.40) | GPR6HTR2AHTR2C | |
| SCHEMBL30013207 | 0.77 | MGLL (0.49) | MGLLHDAC4ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | claimed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | MGLL 4524/4885HDAC4 1611/4885GPR6 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.